In response to daily muscle-activating measures, as previously detailed, Wollersheim et al. found that encoding myostatin gene expression (MSTN) and myostatin plasma levels (a potent negative regulator of muscle mass [19]), generally associated with sarcopenia, were significantly decreased in the intervention group and remained unaffected by the type of intervention. This evidence concerns the gene MSTN and sarcopenia.